Licencing Opportunity:
This work represents a licensing opportunity.
Contact Information: Raymond Dattwyler, MD 18 Woodhull Rd East Setauket, NY 11733, USA
Further Information:
This platform technology can be used develop much needed oral vaccines against microbial pathogens that cause anthrax, tularemia, plague, RSV, pneumoccocal pneumonia (all serotypes), EPEC and malaria. It can also be applied to develop therapies against chronic intestinal inflammatory diseases (Crohn’s Disease) and autoimmune diseases.
Oral immunization with recombinant Lactobacillus plantarum induces a protective immune response in the Lyme disease mouse model.
Clinical and vaccine immunology : CVI 2008 Jul 16; In press
Del Rio B B, Dattwyler R RJ, Aroso M M, Neves V V, Meirelles L L, Seegers J JF, Gomes-Solecki M M
Department of Microbiology and Immunology, New York Medical College, Valhalla, NY, USA; Biopeptides Corp., Valhalla, NY, USA; Falco Biotherapeutics BV (previously Lactrys Biopharmaceuticals BV), Zernikedreef 9, 2331 CK Leiden, The Netherlands.
Mucosal immunization is advantageous over other routes of antigen delivery because it can induce both mucosal and systemic immune responses. Our goal was to develop a mucosal delivery vehicle based on bacteria "generally regarded as safe", such as Lactobacillus spp. In this study, we used the Lyme disease mouse model as a proof of concept. We demonstrate that an oral vaccine based in live recombinant Lactobacillus plantarum protects mice from tick transmitted Borrelia burgdorferi infection. Our method of expressing vaccine antigens in L. plantarum induces both systemic and mucosal immunity after oral administration. This platform technology can be applied to design oral vaccine delivery vehicles against several microbial pathogens.
Keywords: Lactobacillus plantarum Lyme disease